When more than 18,000 cancer specialists from around the world gathered in Los Angeles for the 34th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 16 to 19, the media was there to greet them with microphones bristling, cameras rolling, and laptops at hand. And for good reason, according to ASCO president Robert J. Mayer, MD. The results of more than 2,000 new studies presented at the meeting, including information about the relative benefits of tamoxifen and ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Printer-friendly, you'll get exclusive access to a large archive of premium content.

Already registered? here.